COMPASS Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression.
Serious fucking DD for you retards
- Both Phase 3 trials met their primary endpoints with statistically significant results.
- COMP360 has FDA Breakthrough Therapy designation and the company is progressing toward an NDA.
- If approved, it could become the first major regulated psilocybin treatment and own a very memeable category.
- The stock still offers serious upside if approval and commercial adoption land. Which it fucking will.
Kevin Mak, the legend who was early on both SPHR and (unnamed ass-tits satellite stock) is in. Lot of words in this piece, but they all sound bullish to me https://x.com/i/status/2075541715272790373
Disclosure: NFA, I'm in for 4000 shares at $13.45